Cover Image

Maple Syrup Urine Disease: Incidence and Related Factors in Infants 2008-2015, Tehran, Iran

Bita Najafian, Ehsan Shahverdi, Mohammad Amin Konjedi, Mohammad Tohidi

Background: Maple syrup urine disease is an inherited autosomal recessive disorder. Infants with MSUD appear normal at birth. In Iran, no data concerning the incidence of MSUD has ever been reported. The aims of this study were (a) to estimate the incidence of MSUD in Iran (b) to establish a preliminary comparative analysis of clinical presentation and diagnosis. Materials and Methods: This retrospective analytical study was conducted between 20 March 2008 and 20 February 2015. We evaluated babies born in Najmiyyeh Hospital and referring to Niloo, Masoud and Saeid laboratories in Tehran, Iran. Blood leucine level was measured. Normal leucine levels in blood samples from healthy infants were less than 4.27 mg/dl. In patients whose blood leucine levels were higher, the experiment was repeated once again. If the result was positive again for the final confirmation of the disease in infants, quantitative measurement of amino acids such as leucine, isoleucine and valine was performed by HPLC (high-performance liquid chromatography). The prevalence of MSUD was determined in newborns. Results: Of 200,000 cases, 11 had MSUD. The prevalence was 1:18,180. The mean age of symptom onset was 6±2.8 days. Special diets for MSUD, diet and liver transplantation, diet and blood transfusion and peritoneal dialysis were performed on 9, 1, 1, 1, respectively. Conclusion: We should consider the diagnosis of MSUD in infants with poor feeding, lethargy, smell of burnt sugar in the urine and nneurological involvement.[GMJ.2015;4(4):164-68]

Neonatal; Branched Amino Acids; Maple Syrup Urine Disease; Leucine, Isoleucine; Valine

Pangkanon S, Charoensiriwatana W, Sangtawesin V. Maple syrup urine disease in Thai infants. J Med Assoc Thai. 2008;91(Suppl 3):S41-S4.

Rezvani I, Rosenblatt DS. Valine, leucine, isoleucine, and related organic acidemias. Nelson Textbook of Pediatrics 17th ed Philadelphia: Saunders. 2004:409-33.

Nyhan W, Ozand P. Maple syrup urine disease (branched-chain oxoaciduria). Atlas of metabolic diseases London: Chapman&Hall Medical. 1998:138-46.

Surarit R, Srisomsap C, Wasant P, Svasti J, Suthatvoravut U, Chokchaichamnankit D, et al. Plasma amino acid analyses in two cases of maple syrup urine disease. The Southeast Asian journal of tropical medicine and public health. 1998;30:138-9.

Herber S, Schwartz IVD, Nalin T, Netto CBO, Junior JSC, Santos ML, et al. Maple Syrup Urine Disease in Brazil: a panorama of the last two decades. Jornal de pediatria. 2014.

Chuang D. Disorders of branched chain amino acid and keto acid metabolism. The metabolic and molecular bases of inherited disease. 1995:1239-77.

Chuang D, Shih V. Maple syrup urine disease (branched-chain ketoaciduria). The metabolic and molecular basis of inherited disease. 2001;2:1971-2005.

Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatric research. 2006;59(1):17-20.

Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002;109(6):999-1008.

De Baulny HO, Saudubray J-M. Branched-chain organic acidurias. Inborn Metabolic Diseases. Springer; 2000. p. 196-212.

Westall R. Dietary treatment of maple syrup urine disease. American Journal of Diseases of Children. 1967;113(1):58-9.

Yoshino M, Aoki K, Akeda H, Hashimoto K, Ikeda T, Inoue F, et al. Management of acute metabolic decompensation in maple syrup urine disease: A multi‐center study. Pediatrics international. 1999;41(2):132-7.

Wilcken B. An Introduction to Nutritional Treatment in Inborn Errors of Metabolism-Different Disorders, Different Approaches. SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH. 2004;34:198-201.

Jouvet P, Jugie M, Rabier D, Desgrès J, Hubert P, Saudubray JM, et al. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease. Intensive care medicine. 2001;27(11):1798-806.

Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL, Puffenberger EG, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Molecular genetics and metabolism. 2010;99(4):333-45.

Feier F, Miura I, Fonseca E, Porta G, Pugliese R, Porta A, et al. Successful domino liver transplantation in maple syrup urine disease using a related living donor. Brazilian Journal of Medical and Biological Research. 2014;47(6):522-6.

Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. The Journal of pediatrics. 2012;160(1):116-21. e1.

Tada K, Tateda H, Arashima S, Sakai K, Kitagawa T, Aoki K, et al. Follow-up study of a nation-wide neonatal metabolic screening program in Japan. European journal of pediatrics. 1984;142(3):204-7.

Simon E, Wendel U, Schadewaldt P. Maple syrup urine disease-treatment and outcome in patients of Turkish descent in Germany. Turk J Pediatr. 2005;47:8-13.

Golbahar J, Honardar Z. Selective Screening of Phenylketonuria, Tyrosinemia and Maple Syrup Urine Disease in Southern Iran. 2002.

Quental S, Vilarinho L, Martins E, Teles EL, Rodrigues E, Diogo L, et al. Incidence of maple syrup urine disease in Portugal. Molecular genetics and metabolism. 2010;100(4):385-7.

Niu D-M, Chien Y-H, Chiang C-C, Ho H-C, Hwu W-L, Kao S-M, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. Journal of inherited metabolic disease. 2010;33(2):295-305.

Pico MC, Ramos DC, Fontan MB, Rodriguez AI, De Juan JC, Bermudez JF, editors. Avances en el diagnóstico y tratamiento de la enfermedad de jarabe de arce, experiencia en Galicia. Anales de Pediatria; 2007: Elsevier.

Refbacks

  • There are currently no refbacks.